Lanol-ER

Quick links to important sections

Lanol-ER

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lanol-ER

Quick Facts

Property Description
Active ingredient Acetaminophen (Paracetamol)
Form Extended-Release (ER) Tablet
Pharmacological class Analgesic and Antipyretic
Common use Temporary relief of aches, pain, and fever
Origin Synthetic compound

What Type of Medicine is Lanol-ER?

Lanol-ER is a synthetic pharmaceutical entity classified as an analgesic (pain reliever) and antipyretic (fever reducer). The core medicinal substance is Acetaminophen, which is recognized internationally as Paracetamol. This compound is one of the most widely used analgesics globally, and its efficacy is clinically recognized. As a non-opioid analgesic, it works centrally within the nervous system to modify pain signals and regulate the body's temperature. Acetaminophen is used to treat minor aches and pains and to reduce fever.

Lanol-ER's Unique Composition and Form

Lanol-ER is a single active ingredient product (monotherapy) administered orally as an Extended-Release (ER) tablet. The product is engineered using specialized solid oral excipients to control the dissolution rate of the Acetaminophen, a feature designed for sustained-action drug delivery. This sustained-release formulation is specifically intended for adults and adolescents requiring relief that lasts for an extended period, in contrast to formulations aimed at rapid, short-term symptom relief. Acetaminophen is classified as an effective analgesic.

The General Purpose of Lanol-ER

The primary general purpose of Lanol-ER is to provide temporary relief from persistent aches, minor pains, and to help in fever reduction. The extended-release design serves to maximize the duration of this relief, making it suitable for managing symptoms such as discomfort that lasts through the day or overnight. By utilizing the specific mechanism of its analgesic and antipyretic action, the medication provides consistent, long-lasting symptom management.

Regulatory References

  1. National Institutes of Health MedlinePlus

What side effects are possible with Lanol-ER?

Possible side effects and safety information

The safety profile for Lanol-ER (Acetaminophen/Paracetamol) is primarily characterized by the officially documented potential for Severe Hepatotoxicity, meaning serious liver damage. Regulatory documents classify this risk as the chief safety concern, particularly when the maximum daily limit is exceeded, either through acute overdose or chronic use at high doses. Individuals with existing hepatic impairment or a history of chronic alcohol use are specifically noted in official labeling as having increased vulnerability to this effect.


Adverse reactions are formally organized into specific frequency tiers and system-organ classes in official product information:

Classification System-Organ Class Involved Example Adverse Reactions (Regulatory)
Rare Blood and Lymphatic System Disorders Blood dyscrasias, such as Thrombocytopenia
Rare Immune System Disorders Hypersensitivity reactions, including angioedema
Very Rare Skin and Subcutaneous Tissue Disorders Severe cutaneous reactions (SJS, TEN, AGEP)

Serious Adverse Reactions officially documented also include Anaphylaxis and the Very Rare but life-threatening Severe Cutaneous Adverse Reactions (SCARs). These serious effects necessitate immediate regulatory emphasis.

Regulatory documentation enforces explicit safety restrictions for Lanol-ER. The medicine is formally contraindicated in cases of severe hepatic insufficiency and known severe hypersensitivity to the active ingredient. Furthermore, official labeling restricts the concurrent use of Lanol-ER with any other product containing acetaminophen to mitigate the severe risk of overdose and subsequent liver injury.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory profile for Lanol-ER (Extended-Release Acetaminophen) is defined by the risk of severe, delayed toxicity. The primary documented risk is severe liver damage (hepatotoxicity), which can progress to acute liver failure and potentially death. Initial overdose symptoms such as nausea, vomiting, or abdominal pain may be mild or entirely absent for several days, masking the progression of internal injury. Other potential severe outcomes documented in regulatory sources include coagulopathy, renal failure, metabolic acidosis, and life-threatening skin reactions.

Immediate medical help is required in all cases of suspected overdose, as mandated by regulatory authorities, even if no signs or symptoms are immediately apparent. Individuals must seek emergency medical attention or contact a Poison Control Center right away. The specific antidote, N-acetylcysteine (NAC), is available, but its maximum protective effect is achieved when administered within a critical time window of ingestion. Due to the Extended-Release formulation, specific repeat monitoring of plasma concentration is required to accurately assess toxicity risk, differentiating management from immediate-release formulations. Patients with risk factors like chronic alcohol consumption or hepatic impairment are noted to be at an increased risk of severe hepatic injury.

Therapeutic Uses of Lanol-ER

Lanol-ER (Extended-Release Acetaminophen/Paracetamol) is generally used in areas where short-term symptom management is appropriate. The core compound is commonly used to help with symptoms related to physical discomfort and reduce fever across a range of conditions. It is relevant in contexts marked by increased discomfort or tension and may assist with prolonged symptomatic management.

The medication is considered relevant for easing symptoms related to mild to moderate pain, including common headaches, backache, musculoskeletal soreness, dental discomfort, and cyclical menstrual cramps. It also plays a role in managing symptoms related to systemic imbalance, primarily by reducing elevated body temperature (fever) associated with conditions like the cold or flu. Lanol-ER is applicable within clinical settings that involve acute or disruptive symptom patterns, helping to address symptom clusters that may become intense or disruptive. The extended-release feature is considered relevant when supportive symptom management is appropriate, such as during phases when symptoms become more noticeable and interfere with daily functioning. This consistent action may assist with managing symptoms related to physical discomfort and helps maintain a sense of stability over an extended duration.


Quick Fact: Supportive Symptom Management

Property Description
Primary Focus Mild to moderate pain and fever
Key Benefit Relevant for managing symptoms over an extended duration
Usage Scenario Applied in scenarios where additional management of discomfort is required
Symptom Coverage Headaches, backache, muscle aches, fever

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Lanol-ER is strictly regulated for use based on age and specific pre-existing health conditions, as defined by official regulatory documents.

Populations Allowed and Restricted

Lanol-ER is authorized for Adults and Adolescents aged 12 years and older. Its use is not recommended for children under 12, as the specific extended-release formulation’s suitability is not established for this younger age group.

Absolute Contraindications

The medicine is contraindicated and must not be used by any individual with a known severe allergy or hypersensitivity to acetaminophen or any component of the tablet. An absolute prohibition on use is also imposed for patients with severe active liver disease or severe hepatic impairment, due to the risk associated with the drug’s metabolism.

Conditional Eligibility

Use is considered restricted and requires caution in certain populations. This includes patients with severe renal (kidney) impairment, mild to moderate hepatic impairment, chronic alcoholism, or malnutrition.

For pregnant and breastfeeding women, use is generally considered conditional; it is permitted if clinically necessary, but official regulatory advisories require limiting use to the lowest effective dose for the shortest duration.

What should I know about interactions with other medicines?

The official regulatory profile for Lanol-ER documents interactions primarily focused on clearance, exposure modification, and toxicity risk. Co-administration is formally contraindicated with any other product containing acetaminophen, whether prescription or nonprescription. This restriction is based on the significant, documented risk of severe liver damage (hepatotoxicity).

Pharmacokinetic interactions are officially described for several substances. Probenecid is documented to reduce clearance, which formally results in an increased plasma concentration of Lanol-ER. Conversely, the absorption rate is increased by agents like Metoclopramide and is reduced by Colestyramine, which necessitates a mandated timing separation of at least one hour to avoid this effect.

Interactions affecting the risk of toxicity include enzyme-inducing medicines, such as Carbamazepine and Phenytoin, which accelerate the formation of the hepatotoxic metabolite. The regulatory label also specifies that consuming three or more alcoholic drinks every day increases the risk of severe liver damage. Furthermore, the official profile notes a specific pharmacodynamic effect: prolonged, regular co-use with oral anticoagulants, like Warfarin, may enhance the anticoagulant effect. Regulatory documents also highlight a heightened risk of intoxication for patients with severe hepatic impairment or chronic alcoholism when co-administering certain interacting agents.

Mechanism of Action

Central Prostaglandin Synthesis Inhibition

Lanol-ER acts within the central nervous system (CNS) to modulate key pathways involving cyclooxygenase (COX) enzymes. By interfering with the synthesis of prostaglandins, particularly in the brain and spinal cord, it modifies early molecular steps that shape systemic physiological outcomes. This mechanism contributes to modulating afferent signal processing, influencing the subsequent physiological response profile.


Hypothalamic Thermoregulation Adjustment

The drug engages mechanisms that regulate overactive or dysregulated processes within the hypothalamic heat-regulating center of the brain. The drug promotes a shift in the temperature set point by modulating mediator influence within the pathway, resulting in an altered physiological temperature baseline.

Dosage and Administration Information

How to Use Lanol-ER: Official Administration Guidelines

Lanol-ER is an Extended-Release (ER) Oral Tablet used according to specific instructions to ensure its proper function as a long-acting formulation of acetaminophen. The medication is taken by the oral route.


Standard Dosing and Frequency

Instruction Detail
Standard Dose 1300 mg (two 650 mg Extended-Release tablets).
Frequency Dosed every 8 hours.
Maximum Daily Dose 3900 mg (six 650 mg tablets) in a 24-hour period.

Administration Requirements

To preserve the controlled release of the medicine, the tablet must be swallowed whole and must not be crushed, chewed, split, or dissolved. Each dose should be taken with a full glass of water and may be administered with or without food.

Duration and Population Use

Lanol-ER is designed for short-term use. Use for pain relief is generally limited to 10 days, and use for fever reduction is limited to 3 days, unless a healthcare professional specifies a different duration.

Standard dosing applies to adults and adolescents 12 years of age and over. For pediatric patients under 12, use is generally not recommended, and professional guidance must be sought. For patients with certain conditions, such as renal or hepatic impairment, official guidance may require dose reduction or an extended interval between doses to manage the medicine's clearance.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Lanol-ER

The research base for Lanol-ER involves studies of its active compound, Acetaminophen (Paracetamol), and trials specific to its extended-release design. This overview describes the structure of the evidence used by regulators, focusing on what was studied and where research gaps remain.

Evidence for Use in Temporary Symptom Changes Related to Pain

Research has frequently examined the active compound in Lanol-ER in relation to outcomes related to physical discomfort. Studies conducted during periods of increased symptom activity, such as after a minor procedure or during a common headache, have often involved short-term Randomized Controlled Trials (RCTs). The research involved monitoring physiological metrics and assessed changes in symptom intensity.

Findings describe patterns observed in the studies related to measured changes in pain intensity when compared to a non-active control. However, results apply only to the populations studied, and specific evidence regarding the extended-release formulation across various types of pain remains limited. The generalizability of findings to rare or complex pain syndromes is not well characterized by the existing primary RCT data.

Evidence for Use in Reducing Elevated Body Temperature (Fever)

The evidence base for the drug’s use in elevated body temperature (fever) has been monitored in studies examining temporary physiological imbalance. Data suggest patterns related to measured changes in body temperature and the duration for which this was observed in study populations. This evidence contributes to understanding symptom patterns related to fever, reflecting the active compound's research history.

Research on the Extended-Release Formulation and Sustained Action

This heading describes the specific Pharmacokinetic (PK) trials and Comparative Studies relevant to assessing the sustained-release profile of Lanol-ER. PK studies and some comparative trials reported patterns related to the slower release of the active ingredient and an extended duration for which symptomatic change was observed in some studies. Comparative evidence is lacking to establish its performance relative to appropriately dosed immediate-release formulations. Long-term effects are not fully established, and data for certain groups remain insufficient.

Key Studies & References Acetaminophen (National Institutes of Health MedlinePlus Drug Information)

Frequently Asked Questions (FAQ)

Common questions about Lanol-ER (FAQ)


Q: Is Lanol-ER FDA-approved?

A: Yes, the active ingredient in the Lanol-ER extended-release formulation is an approved product, as referenced in the official FDA prescribing information. Official documentation indicates the drug is authorized for the uses described in its regulatory label.


Q: Is Lanol-ER a type of antibiotic?

A: No, Lanol-ER is classified in official documents as an analgesic (pain reliever) and an antipyretic (fever reducer). It is not an antibiotic and does not treat bacterial infections.


Q: What is the main difference between Lanol-ER and Lanol-IR?

A: Lanol-ER is an Extended-Release (ER) formulation, which is specifically designed to dissolve slowly over time to provide a sustained effect. Immediate-Release (IR) formulations release the medication quickly into the body for rapid onset of action.


Q: How does the extended-release feature of Lanol-ER benefit the user?

A: The extended-release feature is engineered to control the rate at which the active ingredient enters the body. This design helps provide relief over a longer period, which is designed for managing symptoms requiring longer-lasting relief.


Q: What does 'extended-release' mean for the way the drug works?

A: Extended-release means the tablet is formulated to dissolve slowly in the body. This controlled delivery mechanism ensures the medication is released gradually, intended to sustain the effect over a longer duration.


Q: Is Lanol-ER used for short-term or long-term treatment?

A: Lanol-ER is specifically designed and regulated for short-term use. Official product information generally limits use to 10 days for pain relief and 3 days for fever reduction, unless otherwise specified by a healthcare professional.


Q: What happens if I take Lanol-ER for longer than recommended?

A: Official warnings state that taking the drug for longer than the recommended short-term duration may increase the risk of severe liver damage, known as hepatotoxicity. This risk is documented to increase when the maximum daily dose is exceeded.


Q: What are the most common reasons a doctor would prescribe Lanol-ER?

A: It is generally described as being prescribed to provide temporary, long-lasting relief of persistent minor aches, pains, and fever, especially when an extended-release formulation is deemed appropriate.


Q: Is Lanol-ER linked to liver issues?

A: Yes. The most serious risk documented is severe liver damage (hepatotoxicity). This risk is the central focus of official warnings regarding maximum dosage and concurrent alcohol use.


Q: Are there any known drug interactions that are life-threatening?

A: The risk of severe hepatotoxicity (liver damage) is significantly increased to a life-threatening level if Lanol-ER is used concurrently with any other product containing acetaminophen. Official regulatory documents emphasize the importance of avoiding this combination.


Q: What are the serious but rare side effects of Lanol-ER?

A: Serious adverse reactions officially documented include Severe Hepatotoxicity (liver damage), Anaphylaxis (severe allergic reaction), and Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome (SJS). These are classified as rare but require immediate attention.


Q: Does Lanol-ER affect sleep?

A: Official regulatory documents do not commonly list sleep-related issues as adverse reactions for the active ingredient alone. Side effects are typically classified by frequency in the official product information.


Q: Can Lanol-ER cause dizziness or drowsiness?

A: Official prescribing information for the active ingredient alone does not typically list dizziness or drowsiness as common side effects. Individuals may monitor their response to the medication.


Q: Can you drive while taking Lanol-ER?

A: The active ingredient does not commonly cause significant drowsiness or impaired concentration. Caution is generally advised when driving or operating machinery until an individual is aware of their personal response to the medication.


Q: Is there a risk of dependence or addiction with Lanol-ER?

A: Lanol-ER is classified as a non-opioid analgesic and, according to official information, is not associated with a risk of dependence or addiction when taken as directed.


Q: Does Lanol-ER affect blood pressure?

A: Some research has examined the potential for the active ingredient to cause minor increases in blood pressure in certain patients. However, the medicine is generally regarded as suitable for cardiovascular patients compared to other classes of pain relievers.


Q: What if I experience unusual swelling while using Lanol-ER?

A: Unusual swelling, particularly of the face, mouth, or throat, is documented as a symptom of a possible severe hypersensitivity reaction (a serious allergic response). This is a rare, but serious, event that requires immediate medical attention.


Q: Has Lanol-ER been studied in children? (Under 12)

A: Lanol-ER is authorized for adults and adolescents aged 12 and older. The medicine is not recommended for children under 12 years of age because the safety and suitability of this specific extended-release formulation are not established for that age group.


Q: Is Lanol-ER safe for use in older adults?

A: The standard dosage is described in official documents for adults. However, official guidance notes that dosage adjustments may be required for individuals with underlying health issues common in older adults, such as renal or hepatic impairment (kidney or liver problems).


Q: Are there any special warnings for people with heart problems using Lanol-ER?

A: The active ingredient is generally considered suitable for use in patients with cardiovascular disease. While routine use does not have specific warnings for heart problems, the need for blood pressure monitoring may be indicated in some cases.


Q: Are there specific tests I need before starting Lanol-ER?

A: Official documents indicate that routine monitoring may be advised for high-risk patients or those on chronic therapy. This may include tests for liver function and renal function (kidney function) before or during use.


Q: Are there any food or drink restrictions while taking Lanol-ER?

A: The main restriction is against consuming three or more alcoholic drinks every day, as this significantly increases the risk of severe liver damage. Otherwise, the medication may be administered with or without food.


Q: Does Lanol-ER interact with vitamins or herbal supplements?

A: Official documents specify interactions with certain prescription drugs and alcohol. The regulatory information does not comprehensively list all possible interactions with every vitamin or herbal supplement, so reviewing the full list of medications is generally advised.


Q: Does Lanol-ER affect birth control effectiveness?

A: The active ingredient may have a minor impact on how oral contraceptives are cleared by the body. However, regulatory information suggests this is not typically associated with a significant risk of reducing the effectiveness of birth control at usual doses.


Q: Does Lanol-ER contain lactose or gluten?

A: The official FDA label lists all inactive ingredients (excipients) used in the tablet. Information on whether these excipients are derived from common allergens like lactose or gluten can be confirmed by reviewing the full prescribing information.


Q: What is the half-life of Lanol-ER?

A: The elimination half-life (the time it takes for half the drug to be eliminated from the body) of the active compound (acetaminophen) is generally reported in literature to be approximately 2 to 4 hours in adults.


Q: How long does Lanol-ER stay in your system?

A: Based on the half-life of its active ingredient, the drug is generally cleared from the body within a day of the last dose. The extended-release format maintains the desired effect over a longer period than immediate-release forms.

How should Lanol-ER be stored and disposed of?

How to Store and Dispose of Lanol-ER (Extended-Release Acetaminophen)

Lanol-ER must be stored according to regulatory specifications to maintain its stability. The product requires storage at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The medication must be protected from excessive heat, moisture, and light and should not be refrigerated or frozen.

Handling and Child Safety

The tablets should remain in their original, tightly closed container until use. A mandatory storage requirement is keeping Lanol-ER out of the sight and reach of children and pets to prevent accidental ingestion.

Disposal

Official disposal guidance recommends using a drug take-back program or mail-back service for unused or expired tablets. If those options are unavailable, the medication may be disposed of in the household trash by mixing the whole (uncrushed) tablets with an undesirable substance, such as coffee grounds or dirt, sealing the mixture, and discarding it.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lanol-ER found in:

A-Z Index: